Related Experiment Video
Updated: Jul 13, 2026
Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
Published on: May 4, 2015
Evaluation of two commercially available anti human immunodeficiency virus antibody ELISA Kits using clinical samples
K Anuradha1, S P D Ponamgi, V Lakshmi
1Dept. of Microbiology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad - 500 082, India.
Insights
Evaluating the Microlisa HIV kit demonstrated 100% sensitivity and specificity for detecting anti-HIV antibodies. This diagnostic tool is recommended for primary screening of human immunodeficiency virus (HIV) infection due to its efficiency and ease of use.
Area of Science:
- Medical Diagnostics
- Immunology
- Virology
Background:
- Laboratory diagnosis is crucial for identifying human immunodeficiency virus (HIV) infection.
- A variety of diagnostic kits for detecting anti-HIV antibodies necessitate thorough evaluation before market release.
Purpose of the Study:
- To evaluate the performance of the Microlisa HIV kit.
- To assess the diagnostic accuracy of the Microlisa HIV kit compared to a reference standard.
Main Methods:
- Performance evaluation of the Microlisa HIV kit (J. Mitra & Co.).
- Utilized a clinical specimen panel comprising both HIV-reactive and non-reactive samples.
- Comparative analysis against the UBI HIV 1/2 EIA kit.
Main Results:
- The Microlisa HIV kit achieved 100% sensitivity.
- The Microlisa HIV kit demonstrated 100% specificity.
- Performance was benchmarked against the UBI HIV 1/2 EIA kit.
Conclusions:
- The Microlisa HIV kit exhibits excellent diagnostic performance (100% sensitivity and specificity).
- Its ease of testing and efficient assay characteristics support its use as a primary screening tool for HIV infection in laboratories.
Abstract:
Laboratory diagnosis is the mainstay in the diagnosis of HIV infection in an individual. The wide range of diagnostic kits available, for the detection of anti HIV antibodies, makes it mandatory that the kits are evaluated before they are made available in the market. We evaluated the performance of a Microlisa HIV kit (J. Mitra & Co.) using a panel of HIV reactive and non reactive clinical specimens. The sensitivity and specificity of the kit were found to be 100% as compared to the UBI HIV 1/2 EIA kit. The ease of testing, the assay characteristics including efficiency of the Microlisa favour its use by laboratories as a primary screen for HIV infection.
